Giselle L Saulnier Sholler
Overview
Explore the profile of Giselle L Saulnier Sholler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith K, Trovillion E, Sholler C, Gandra D, McKinney K, Mulama D, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518006
The survival rate of patients with Ewing sarcoma (EWS) has seen very little improvement over the past several decades and remains dismal for those with recurrent or metastatic disease. HDAC2,...
2.
Gandra D, Mulama D, Foureau D, McKinney K, Kim E, Smith K, et al.
Cancer Med
. 2024 Apr;
13(9):e7207.
PMID: 38686627
Background: Most high-risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event-free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance...
3.
Saulnier Sholler G, Bergendahl G, Lewis E, Kraveka J, Ferguson W, Nagulapally A, et al.
Genome Med
. 2024 Feb;
16(1):28.
PMID: 38347552
Background: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and...
4.
Oesterheld J, Ferguson W, Kraveka J, Bergendahl G, Clinch T, Lorenzi E, et al.
J Clin Oncol
. 2023 Oct;
42(1):90-102.
PMID: 37883734
Purpose: Long-term survival in high-risk neuroblastoma (HRNB) is approximately 50%, with mortality primarily driven by relapse. Eflornithine (DFMO) to reduce risk of relapse after completion of immunotherapy was investigated previously...
5.
Eslin D, Zage P, Bergendahl G, Lewis E, Roberts W, Kraveka J, et al.
Int J Cancer
. 2023 May;
153(5):1026-1034.
PMID: 37246577
Children with relapsed/refractory (R/R) neuroblastoma (NB) and medulloblastoma (MB) have poor outcomes. We evaluated the efficacy of nifurtimox (Nfx) in a clinical trial for children with R/R NB and MB....
6.
Kraveka J, Lewis E, Bergendahl G, Ferguson W, Oesterheld J, Kim E, et al.
Cancer Rep (Hoboken)
. 2022 Mar;
5(11):e1616.
PMID: 35355452
Background: Survival for patients with high-risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. Aims: To study the feasibility and safety of incorporating a genomic-based targeted agent to induction therapy...
7.
Byron S, Hendricks W, Nagulapally A, Kraveka J, Ferguson W, Brown V, et al.
Cancer Res
. 2021 Oct;
81(23):5818-5832.
PMID: 34610968
Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here the genomic and transcriptomic landscapes of...
8.
Lewis E, Kraveka J, Ferguson W, Eslin D, Brown V, Bergendahl G, et al.
Int J Cancer
. 2020 May;
147(11):3152-3159.
PMID: 32391579
Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long-term prognosis for patients with high-risk neuroblastoma (HRNB) remains poor despite aggressive multimodal...
9.
Saulnier Sholler G, Ferguson W, Bergendahl G, Bond J, Neville K, Eslin D, et al.
Sci Rep
. 2018 Sep;
8(1):14445.
PMID: 30262852
High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This...
10.
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, et al.
Pediatr Blood Cancer
. 2015 Aug;
63(1):39-46.
PMID: 26235333
Background: The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and...